

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/Capplus enhanced with utility model patents from China
NEWS 6 JUL 16 Capplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/Capplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 BEILSTEIN updated with new compounds
NEWS 12 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 13 AUG 13 CA/Capplus enhanced with additional kind codes for granted patents
NEWS 14 AUG 20 CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS 15 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16 AUG 27 USPATOLD now available on STN
NEWS 17 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19 SEP 13 FORIS renamed to SOFIS
NEWS 20 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 21 SEP 17 CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS 22 SEP 17 Capplus coverage extended to include traditional medicine patents
NEWS 23 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 24 OCT 02 CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:37:59 ON 09 OCT 2007

=> file medline
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 16:38:20 ON 09 OCT 2007

FILE LAST UPDATED: 6 Oct 2007 (20071006/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate

substance identification.

```
=> s (compound inhibits SGK1)
      127281 COMPOUND
      109374 INHIBITS
      211 SGK1
L1      0 (COMPOUND INHIBITS SGK1)
        (COMPOUND(W) INHIBITS(W) SGK1)

=> s (inhibit? SGK1 or modulate? SGK1)
      1370561 INHIBIT?
      211 SGK1
      1 INHIBIT? SGK1
        (INHIBIT?(W) SGK1)
      125573 MODULATE?
      211 SGK1
      1 MODULATE? SGK1
        (MODULATE?(W) SGK1)
L2      2 (INHIBIT? SGK1 OR MODULATE? SGK1)
```

=> d 1-2

L2 ANSWER 1 OF 2 MEDLINE on STN

Full Text

AN 2006141706 MEDLINE
DN PubMed ID: 16483548
TI Stimulation of serum- and glucocorticoid-regulated kinase-1 gene
expression by endothelin-1.
AU Wolf Sabine C; Schultze Michael; Risler Teut; Rieg Timo; Lang Florian;
Schulze-Osthoff Klaus; Brehm Bernhard R
CS Medical Clinic IV, Section of Nephrology, Hypertension and Renal Failure,
University of Tübingen, Germany.
SO Biochemical pharmacology, (2006 Apr 14) Vol. 71, No. 8, pp. 1175-83.
Electronic Publication: 2006-02-17.
Journal code: 0101032. ISSN: 0006-2952.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200604
ED Entered STN: 14 Mar 2006
Last Updated on STN: 26 Apr 2006
Entered Medline: 25 Apr 2006

L2 ANSWER 2 OF 2 MEDLINE on STN

Full Text

AN 2005203220 IN-PROCESS
DN PubMed ID: 15838307
TI Endothelin-1 Increases Serum-glucocorticoid-regulated Kinase-1 Expression
in Smooth Muscle Cells.
AU Wolf Sabine C; Schultze Michael; Sauter Gabriele; Risler Teut; Brehm
Bernhard R
CS Medical Clinic III, Department of Cardiology, Hypertension and Renal
Failure, University of Tuebingen, Germany.
SO Journal of cardiovascular pharmacology, (2004 Nov) Vol. 44 Suppl 1, pp.
S304-6.
Journal code: 7902492. ISSN: 0160-2446.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20 Apr 2005
Last Updated on STN: 14 Dec 2005

=> file ca

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.12

1.33

FILE 'CA' ENTERED AT 16:39:31 ON 09 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Oct 2007 VOL 147 ISS 16
FILE LAST UPDATED: 4 Oct 2007 (20071004/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s (inhibit? SGK1 or modulate? SGK1)/ab,bi
    1624252 INHIBIT?/AB
        211 SGK1/AB
            1 INHIBIT? SGK1/AB
                ((INHIBIT?(W)SGK1)/AB)
    1919277 INHIBIT?/BI
        260 SGK1/BI
            2 INHIBIT? SGK1/BI
                ((INHIBIT?(W)SGK1)/BI)
    129011 MODULATE?/AB
        211 SGK1/AB
            1 MODULATE? SGK1/AB
                ((MODULATE?(W)SGK1)/AB)
    146545 MODULATE?/BI
        260 SGK1/BI
            1 MODULATE? SGK1/BI
                ((MODULATE?(W)SGK1)/BI)
L3      3 (INHIBIT? SGK1 OR MODULATE? SGK1)/AB,BI

=> d 1-3
```

L3 ANSWER 1 OF 3 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 144:325109 CA
TI Stimulation of serum- and glucocorticoid-regulated kinase-1 gene expression by endothelin-1
AU Wolf, Sabine C.; Schultze, Michael; Risler, Teut; Rieg, Timo; Lang, Florian; Schulze-Osthoff, Klaus; Brehm, Bernhard R.
CS Medical Clinic IV, Section of Nephrology, Hypertension and Renal Failure, University of Tuebingen, Germany
SO Biochemical Pharmacology (2006), 71(8), 1175-1183
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier B.V.
DT Journal
LA English
RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 142:149089 CA
TI Endothelin-1 increases serum-glucocorticoid-regulated kinase-1 expression in smooth muscle cells
AU Wolf, Sabine C.; Schultze, Michael; Sauter, Gabriele; Risler, Teut; Brehm, Bernhard R.
CS Medical Clinic III, Department of Cardiology, Hypertension and Renal Failure, University of Tuebingen, Tuebingen, Germany
SO Journal of Cardiovascular Pharmacology (2004), 44(Suppl. 1), S304-S306
CODEN: JCPCDT; ISSN: 0160-2446

PB Lippincott Williams & Wilkins
DT Journal
LA English

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 141:236715 CA
TI Sgk1 as diagnostic and therapeutic target
IN Lang, Florian
PA Germany
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004079003	A1	20040916	WO 2003-EP2163	20030303
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2517958	A1	20040916	CA 2003-2517958	20030303
	AU 2003215623	A1	20040928	AU 2003-215623	20030303
	EP 1613766	A1	20060111	EP 2003-816137	20030303
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003018166	A	20060404	BR 2003-18166	20030303
	CN 1771330	A	20060510	CN 2003-826398	20030303
	JP 2006518992	T	20060824	JP 2004-569000	20030303
	MX 2005PA09292	A	20060321	MX 2005-PA9292	20050831
	IN 2005KN01729	A	20060922	IN 2005-KN1729	20050831
	US 2007059695	A1	20070315	US 2006-547746	20060926
PRAI	WO 2003-EP2163	W	20030303		

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file uspatall
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
20.10	21.43

FILE 'USPATFULL' ENTERED AT 16:41:13 ON 09 OCT 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 16:41:13 ON 09 OCT 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:41:13 ON 09 OCT 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (inhibit? SGK1 or modulate? SGK1)
L4 4 (INHIBIT? SGK1 OR MODULATE? SGK1)

=> s (inhibit? SGK1 or modulate? SGK1)/clm
L5 1 (INHIBIT? SGK1 OR MODULATE? SGK1)/CLM

=> d

L5 ANSWER 1 OF 1 USPATFULL on STN

Full Text

AN 2007:218365 USPATFULL
TI Methods for altering insulin secretion

IN Lang, Florian, Tuebingen, GERMANY, FEDERAL REPUBLIC OF
 PI US 2007191325 A1 20070816
 AI US 2005-591909 A1 20050210 (10)
 WO 2005-EP1322 20050210
 20060907 PCT 371 date
 PRAI EP 2004-5404 20040308
 DT Utility
 FS APPLICATION
 LN.CNT 713
 INCL INCLM: 514/179.000
 NCL NCLM: 514/179.000
 IC IPCI A61K0031-573 [I,A]; A61K0031-57 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 14 1-4

L4 ANSWER 1 OF 4 USPATFULL on STN

Full Text

AN 2007:218365 USPATFULL
 TI Methods for altering insulin secretion
 IN Lang, Florian, Tuebingen, GERMANY, FEDERAL REPUBLIC OF
 PI US 2007191325 A1 20070816
 AI US 2005-591909 A1 20050210 (10)
 WO 2005-EP1322 20050210
 20060907 PCT 371 date
 PRAI EP 2004-5404 20040308
 DT Utility
 FS APPLICATION
 LN.CNT 713
 INCL INCLM: 514/179.000
 NCL NCLM: 514/179.000
 IC IPCI A61K0031-573 [I,A]; A61K0031-57 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 4 USPATFULL on STN

Full Text

AN 2007:68449 USPATFULL
 TI Sgk1 as diagnostic and therapeutic target
 IN Lang, Florian, Tuebingen, GERMANY, FEDERAL REPUBLIC OF
 PI US 2007059695 A1 20070315
 AI US 2003-547746 A1 20030305 (10)
 WO 2003-EP2163 20030305
 20060926 PCT 371 date
 DT Utility
 FS APPLICATION
 LN.CNT 552
 INCL INCLM: 435/006.000
 INCLS: 435/007.200
 NCL NCLM: 435/006.000
 NCLS: 435/007.200
 IC IPCI C12Q0001-68 [I,A]; G01N0033-567 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 4 USPATFULL on STN

Full Text

AN 2006:282165 USPATFULL
 TI Substituted phenoxazines and acridones as inhibitors of AKT
 IN Houghton, Peter J., Memphis, TN, UNITED STATES
 Thimmaiah, Kuntebommenahalli N., Memphis, TN, UNITED STATES
 Easton, John B., Horn Lake, MS, UNITED STATES
 PA St. Jude Children's Research Hospital, Memphis, TN, UNITED STATES (U.S. corporation)
 PI US 2006241108 A1 20061026
 AI US 2006-367161 A1 20060303 (11)
 PRAI US 2005-658852P 20050303 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3688
 INCL INCLM: 514/229.800
 NCL NCLM: 514/229.800
 IC IPCI A61K0031-538 [I,A]; A61K0031-5375 [I,C*]

IPCR A61K0031-5375 [I,C]; A61K0031-538 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 4 USPATFULL on STN

Full Text

AN 2006:198468 USPATFULL
TI Methods
IN Cohen, Philip, Dundee, UNITED KINGDOM
Kobayashi, Takayasu, Dundee, UNITED KINGDOM
Deak, Maria, Dundee, UNITED KINGDOM
PA The University of Dundee, Dundee, UNITED KINGDOM (non-U.S. corporation)
PI US 7083511 B1 20060801
WO 2000035940 20000622
AI US 1999-868131 19991214 (9)
WO 1999-GB4232 19991214
20020411 PCT 371 date
PRAI GB 1999-19676 19990819
US 1998-112217P 19981214 (60)
DT Utility
FS GRANTED
LN.CNT 3407
INCL INCLM: 453/015.000
INCLS: 435/194.000; 530/300.000; 530/350.000; 536/023.200
NCL NCLM: 453/015.000
NCLS: 435/194.000; 530/300.000; 530/350.000; 536/023.200
IC IPCI C12Q0001-48 [I,A]; C12N0009-12 [N,A]; C12N0001-20 [N,A];
C07H0021-04 [N,A]; C07H0021-00 [N,C*]
IPCR C12Q0001-48 [I,C]; C12Q0001-48 [I,A]; C07H0021-00 [N,C];
C07H0021-04 [N,A]; C12N0001-20 [N,C]; C12N0001-20 [N,A];
C12N0009-12 [N,C]; C12N0009-12 [N,A]
EXF 435/15; 435/194; 530/350; 530/300; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l4 an ti in pi kwic 1-4

L4 ANSWER 1 OF 4 USPATFULL on STN

Full Text

AN 2007:218365 USPATFULL
TI Methods for altering insulin secretion
IN Lang, Florian, Tuebingen, GERMANY, FEDERAL REPUBLIC OF
PI US 2007191325 A1 20070816
SUMM A method for altering insulin secretion comprising, contacting a
pancreatic islet cell expressing SGK1 with a substance that **modulates**
SGK1 and wherein the inhibition of SGK1 involves reversal of the
depolarizing effect of glucose, causing activation of voltage gated
calcium-channels.
SUMM . . . compounds that are useful to restore insulin secretion by
contacting a pancreatic islet cell expressing SGK1 with a substance that
modulates SGK1. Thus the depolarizing effect of glucose is reversed
resulting in activation of voltage gated calcium-channels and subsequent
insulin release.
CLM What is claimed is:
1. A method for altering insulin secretion comprising, contacting a
pancreatic islet cell expressing SGK1 with a substance that **modulates**
SGK1.

L4 ANSWER 2 OF 4 USPATFULL on STN

Full Text

AN 2007:68449 USPATFULL
TI Sgk1 as diagnostic and therapeutic target
IN Lang, Florian, Tuebingen, GERMANY, FEDERAL REPUBLIC OF
PI US 2007059695 A1 20070315
SUMM . . . coagulopathies) as well as hepatogenic, cardiogenic and
immune. coagulopathies, corresponding to the site of the cause.
Consequently, by activating or **inhibiting sgk1**, the disposition of
the blood to coagulate can be decreased or increased and thereby adapted
to the medical indication. Similar.
DETD . . . cells, with subsequent metastasis, and increase angiogenesis.
Conversely, this mechanism would be suppressed by suppressing sgk1
expression or by pharmacologically **inhibiting sgk1**.

L4 ANSWER 3 OF 4 USPATFULL on STN

Full Text

AN 2006:282165 USPATFULL
TI Substituted phenoxazines and acridones as inhibitors of AKT
IN Houghton, Peter J., Memphis, TN, UNITED STATES
Thimmaiah, Kuntebommenahalli N., Memphis, TN, UNITED STATES
Easton, John B., Horn Lake, MS, UNITED STATES
PI US 2006241108 A1 20061026
DETD 7.6. Phenoxazines Do Not **Inhibit SGK1** or PDK1 Kinase Activity

L4 ANSWER 4 OF 4 USPATFULL on STN

Full Text

AN 2006:198468 USPATFULL
TI Methods
IN Cohen, Philip, Dundee, UNITED KINGDOM
Kobayashi, Takayasu, Dundee, UNITED KINGDOM
Deak, Maria, Dundee, UNITED KINGDOM
PI US 7083511 B1 20060801
WO 2000035940 20000622
DETD . . . 19). Serum was also a weak activator of all three isoforms.
However, osmotic shock (treatment with 0.4M sorbitol), which potently
inhibited SGK1, had no effect on the activity of SGK2 α or SGK3
(FIG. 19).

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.88

36.31

STN INTERNATIONAL LOGOFF AT 16:43:44 ON 09 OCT 2007